
Geovax Labs (GOVX) Stock Forecast & Price Target
Geovax Labs (GOVX) Analyst Ratings
Bulls say
Geovax Labs is a clinical-stage biotechnology company with a positive outlook due to its diversified vaccine portfolio for diseases such as smallpox and COVID-19. With multiple key catalysts approaching, including the planned Phase 3 immunobridging study for GEO-MVA in late 2026 and potential data in 2027, and the advancement of the Gedeptin checkpoint inhibitor combination strategy in oncology, the company has significant potential for long-term growth. However, the stock is unlikely to see near-term share price support due to the longer timeline for value realization. Additionally, while the company's AGE1 manufacturing platform solves supply constraints, its constrained balance sheet may require additional dilution to fund ongoing clinical development and working capital needs.
Bears say
Geovax Labs is facing a constrained near-term outlook due to limited catalysts and tightening capital resources, prompting analyst expectations to be lowered from Buy to Hold. The company's strategic focus on advancing GEO-MVA, its mpox/smallpox vaccine candidate, shows potential but the balance sheet remains a key limiting factor. The completed $1M registered direct offering highlights financing challenges, indicating a likelihood of additional dilutive capital raises. The company reported a decline in revenue and improved net loss for 2025, with a decrease in R&D expenses but an increase in G&A expenses. With low liquidity at the end of 2025, external funding will likely be necessary to fully execute on their late-stage development plans.
This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.
Geovax Labs (GOVX) Analyst Forecast & Price Prediction
Start investing in Geovax Labs (GOVX)
Order type
Buy in
Order amount
Est. shares
0 shares